Various forms of cancer continue to be diagnosed every year. In the United States alone, 2.1% of the population will receive a lymphoma diagnosis during their lifetime. On an annual basis, more than 7,200 new cases are diagnosed in this country. When taking all types of new cancer diagnoses into consideration, lymphoma, as well as leukemia and myeloma, account for 10.2% of these.
Insulin-Like Growth Factor and Breast Cancer
According to the University of Chicago’s recent study, the Insulin-like Growth Factor (IGF) pathway has been implicated with several major forms of cancer. In addition to colon and prostate cancer, this includes breast cancer.
One study in particular discovered that IGF receptors are actually 43-times more extensive on breast cancer cells than on breast tissue which is normal. Furthermore, malignant cells possess more IGF-1 receptors than healthy cells. When examining aggressive cancer cells, it has been determined that they have the highest number of IGF-1 receptors. As a result, the presence of these receptors are considered to be effective breast cancer indicators, as increased levels have been located in 80% of women’s breast cancer tumors.
Advances in Cancer Treatment
Cancer research and treatment development is an ongoing pursuit. Due to the advancements that have been made with improving treatment, individuals with non-Hodgkin lymphoma now have a greater survival rate. At one point, this survival rate was five years. Currently, however, it has increased to 74%.
One of the first-known treatments for breast cancer was Methotrexate. It has been used clinically for more than 70 years. It’s important to note that IGF Methotrexate has been determined to be 6.25 times more effective than Methotrexate in order to inhibit the growth of prostate cancer cells.
Investment Opportunities with Oncology Biotech Companies
Since you’re searching for an investment opportunity, you may be interested to learn more about the advancements made by oncology biotech companies. In addition to investing in small biotech companies, you may prefer the option of investing in biotech startups. In addition to making an investment in emerging biotech stocks, there are other opportunities to make a difference within this area of medicine.